HRMY vs. BMY
HRMY (Harmony Biosciences Holdings, Inc.) and BMY (Bristol-Myers Squibb Company) are both stocks. Both are in the Healthcare sector — HRMY in Biotechnology, BMY in Drug Manufacturers - General. Over the past 5 years, HRMY returned 6.14%/yr vs 3.38%/yr for BMY. Their 0.22 correlation means their historical movements had little consistent relationship.
Performance
HRMY vs. BMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, HRMY achieves a -5.83% return, which is significantly lower than BMY's 25.17% return.
HRMY
- 1D
- -1.73%
- 1M
- -5.42%
- 6M
- -3.50%
- YTD
- -5.83%
- 1Y
- 2.44%
- 3Y*
- 1.21%
- 5Y*
- 6.14%
- 10Y*
- —
- ALL TIME*
- -2.10%
BMY
- 1D
- 0.69%
- 1M
- 12.35%
- 6M
- 21.21%
- YTD
- 25.17%
- 1Y
- 54.75%
- 3Y*
- 6.92%
- 5Y*
- 3.38%
- 10Y*
- 2.16%
- ALL TIME*
- 9.43%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $711.50M | $665.03M | $681.59M | |
| $30.21M | $30.03M | $28.08M |
HRMY vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
HRMY Harmony Biosciences Holdings, Inc. | -5.83% | 8.75% | 6.53% | -41.38% | 29.22% | 17.95% | -9.60% |
BMY Bristol-Myers Squibb Company | 25.17% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | -0.06% |
Correlation
The correlation between HRMY and BMY is 0.26, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.26 |
Correlation (3Y) Balances recent behavior with more history. | 0.21 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.24 |
Correlation (All Time) Calculated using the full available price history since Aug 19, 2020 | 0.22 |
Fundamentals
HRMY:
$2.04B
BMY:
$133.37B
HRMY:
$2.48
BMY:
$4.54
HRMY:
14.21
BMY:
14.37
HRMY:
0.14
BMY:
0.82
HRMY:
2.30
BMY:
2.71
HRMY:
2.28
BMY:
5.99
HRMY:
$899.11M
BMY:
$49.19B
HRMY:
$688.25M
BMY:
$34.51B
HRMY:
$221.74M
BMY:
$16.67B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
HRMY vs. BMY — Risk / Return Rank
HRMY
BMY
HRMY vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Harmony Biosciences Holdings, Inc. (HRMY) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| HRMY | BMY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.14 | ||
| Sortino ratioReturn per unit of downside risk | -2.76 | ||
| Omega ratioGain probability vs. loss probability | 1.04 | 1.36 | -0.31 |
| Calmar ratioReturn relative to maximum drawdown | 0.01 | 4.66 | -4.65 |
| Martin ratioReturn relative to average drawdown | 0.01 | 11.09 | -11.08 |
Loading charts...
Drawdowns
HRMY vs. BMY - Drawdown Comparison
The maximum HRMY drawdown since its inception was -68.48%, roughly equal to the maximum BMY drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for HRMY and BMY.
Loading charts...
Drawdown Indicators
| HRMY | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -68.48% | -72.03% | +3.55% |
Max Drawdown (1Y)Largest decline over 1 year | -34.49% | -12.53% | -21.96% |
Max Drawdown (3Y)Largest decline over 3 years | -50.81% | -34.11% | -16.70% |
Max Drawdown (5Y)Largest decline over 5 years | -68.48% | -47.67% | -20.81% |
Max Drawdown (10Y)Largest decline over 10 years | — | -47.67% | — |
Current DrawdownCurrent decline from peak | -42.14% | -4.95% | -37.19% |
Average DrawdownAverage peak-to-trough decline | -35.42% | -22.36% | -13.06% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.24% | 5.25% | +13.99% |
Volatility
HRMY vs. BMY - Volatility Comparison
Harmony Biosciences Holdings, Inc. (HRMY) has a higher volatility of 14.79% compared to Bristol-Myers Squibb Company (BMY) at 9.10%. This indicates that HRMY's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| HRMY | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.79% | 9.10% | +5.69% |
Volatility (6M)Calculated over the trailing 6-month period | 32.46% | 19.64% | +12.82% |
Volatility (1Y)Calculated over the trailing 1-year period | 43.31% | 27.86% | +15.45% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 50.15% | 24.49% | +25.66% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 52.28% | 25.46% | +26.82% |
Dividends
HRMY vs. BMY - Dividend Comparison
HRMY has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 3.84%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 3.84% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
HRMY Harmony Biosciences Holdings, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
HRMY vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Harmony Biosciences Holdings, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HRMY vs. BMY - Profitability Comparison
HRMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Harmony Biosciences Holdings, Inc. reported a gross profit of 170.88M and revenue of 215.39M. Therefore, the gross margin over that period was 79.3%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Bristol-Myers Squibb Company reported a gross profit of 9.25B and revenue of 12.97B. Therefore, the gross margin over that period was 71.3%.
HRMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Harmony Biosciences Holdings, Inc. reported an operating income of 37.29M and revenue of 215.39M, resulting in an operating margin of 17.3%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Bristol-Myers Squibb Company reported an operating income of 4.09B and revenue of 12.97B, resulting in an operating margin of 31.5%.
HRMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Harmony Biosciences Holdings, Inc. reported a net income of 32.49M and revenue of 215.39M, resulting in a net margin of 15.1%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Bristol-Myers Squibb Company reported a net income of 3.32B and revenue of 12.97B, resulting in a net margin of 25.6%.
Frequently Asked Questions
HRMY and BMY have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
HRMY has higher volatility (14.79%) compared to BMY (9.10%). In terms of maximum drawdown, HRMY dropped -68.48% vs BMY's -72.03%.
BMY currently has the higher Sharpe Ratio (2.14 vs 0.00), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for HRMY and BMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer